Preliminary results of a factorial phase II randomized trial of continuous (c) or intermittent (i) docetaxel (DOC) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC) (HOPLITE trial).
Orazio Caffo
No relevant relationships to disclose
Giovanni Lo Re
No relevant relationships to disclose
Teodoro Sava
No relevant relationships to disclose
Sebastiano Buti
No relevant relationships to disclose
Cosimo Sacco
No relevant relationships to disclose
Umberto Basso
No relevant relationships to disclose
Fable Zustovich
No relevant relationships to disclose
Thomas Martini
No relevant relationships to disclose
Alessandra Perin
No relevant relationships to disclose
Antonello Veccia
No relevant relationships to disclose
Lucianna Russo
No relevant relationships to disclose
Gaetano Facchini
No relevant relationships to disclose
Carmen Barile
No relevant relationships to disclose
Angela Gernone
No relevant relationships to disclose
Rocco De Vivo
No relevant relationships to disclose
Giovanni L. Pappagallo
No relevant relationships to disclose
Enzo Galligioni
No relevant relationships to disclose